Search

Your search keyword '"Casadei, Beatrice"' showing total 466 results
Start Over Author "Casadei, Beatrice"
466 results on '"Casadei, Beatrice"'

3. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

Author

Chiappella, Annalisa, Casadei, Beatrice, Chiusolo, Patrizia, Di Rocco, Alice, Ljevar, Silva, Magni, Martina, Angelillo, Piera, Barbui, Anna Maria, Cutini, Ilaria, Dodero, Anna, Bonifazi, Francesca, Tisi, Maria Chiara, Bramanti, Stefania, Musso, Maurizio, Farina, Mirko, Martino, Massimo, Novo, Mattia, Grillo, Giovanni, Patriarca, Francesca, Zacchi, Giulia, Krampera, Mauro, Pennisi, Martina, Galli, Eugenio, Martelli, Maurizio, Ferreri, Andrés J. M., Ferrari, Silvia, Saccardi, Riccardo, Bermema, Anisa, Guidetti, Anna, Miceli, Rosalba, Zinzani, Pier Luigi, and Corradini, Paolo

Published
2024
Full Text
View/download PDF

4. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Author

Voltin, Conrad-Amadeus, Paccagnella, Andrea, Winkelmann, Michael, Heger, Jan-Michel, Casadei, Beatrice, Beckmann, Laura, Herrmann, Ken, Dekorsy, Franziska J., Kutsch, Nadine, Borchmann, Peter, Fanti, Stefano, Kunz, Wolfgang G., Subklewe, Marion, Kobe, Carsten, Zinzani, Pier Luigi, Stelljes, Matthias, Roth, Katrin S., Drzezga, Alexander, Noppeney, Richard, Rahbar, Kambiz, Reinhardt, H. Christian, von Tresckow, Bastian, Seifert, Robert, Albring, Jörn C., Blumenberg, Viktoria, Farolfi, Andrea, Flossdorf, Sarah, Gödel, Philipp, and Hanoun, Christine

Published
2024
Full Text
View/download PDF

6. Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma

Author

Briest, Franziska, Noerenberg, Daniel, Hennch, Cornelius, Yoshida, Kenichi, Hablesreiter, Raphael, Nimo, Jose, Sasca, Daniel, Kirchner, Marieluise, Mansouri, Larry, Inoue, Yoshikage, Wiegand, Laura, Staiger, Annette M., Casadei, Beatrice, Korkolopoulou, Penelope, Weiner, January, Lopez-Guillermo, Armando, Warth, Arne, Schneider, Tamás, Nagy, Ákos, Klapper, Wolfram, Hummel, Michael, Kanellis, George, Anagnostopoulos, Ioannis, Mertins, Philipp, Bullinger, Lars, Rosenquist, Richard, Vassilakopoulos, Theodoros P., Ott, German, Ogawa, Seishi, and Damm, Frederik

Published
2023
Full Text
View/download PDF

7. extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells

Author

Storci, Gianluca, De Felice, Francesco, Ricci, Francesca, Santi, Spartaco, Messelodi, Daria, Bertuccio, Salvatore Nicola, Laprovitera, Noemi, Dicataldo, Michele, Rossini, Lucrezia, De Matteis, Serena, Casadei, Beatrice, Vaglio, Francesco, and Ursi, Margherita

Subjects
Non-Hodgkin's lymphomas -- Care and treatment -- Prognosis, Cell organelles -- Health aspects -- Measurement, Neurotoxicity syndromes -- Risk factors, Biological markers -- Measurement, Health care industry
Abstract

BACKGROUND. Predicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises a few days after infusion, when circulating CAR T cells are scarce and specific CAR T cell- derived biomarkers are lacking. METHODS. [CAR.sup.+] extracellular vesicle ([CAR.sup.+]EV) release was assessed in human CD19.CAR T cells cocultured with [CD19.sup.+] target cells. A prospective cohort of 100 patients with B cell lymphoma infused with approved CD19.CAR T cell products was assessed for plasma [CAR.sup.+]EVs as biomarkers of in vivo CD19.CAR T cell activation. Human induced pluripotent stem cell-derived (iPSC-derived) neural cells were used as a model for [CAR.sup.+]EV-induced neurotoxicity. RESULTS. In vitro release of [CAR.sup.+]EVs occurs within 1 hour after target engagement. Plasma [CAR.sup.+]EVs are detectable 1 hour after infusion. A concentration greater than 132.8 [CAR.sup.+]EVs/[micro]L at hour +1 or greater than 224.5 [CAR.sup.+]EVs/[micro]L at day +1 predicted ICANS in advance of 4 days, with a sensitivity and a specificity outperforming other ICANS predictors. [ENO2.sup.+] nanoparticles were released by iPSC-derived neural cells upon [CAR.sup.+]EV exposure and were increased in plasma of patients with ICANS. CONCLUSION. Plasma [CAR.sup.+]EVs are an immediate signal of CD19.CAR T cell activation, are suitable predictors of neurotoxicity, and may be involved in ICANS pathogenesis. TRIAL REGISTRATION. NCT04892433, NCT05807789. FUNDING. Life Science Hub-Advanced Therapies (financed by Health Ministry as part of the National Plan for Complementary Investments to the National Recovery and Resilience Plan [NRRP]: E.3 Innovative health ecosystem for APC fees and immunomonitoring)., Introduction Anti-CD19 chimeric antigen receptor T (CD19.CAR T) cell therapy changed the treatment of B cell malignancies (1). So far, three CD19.CAR T cell products have received approval from regulatory [...]

Published
2024
Full Text
View/download PDF

8. CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study

Author

Pensato, Umberto, Amore, Giulia, Muccioli, Lorenzo, Sammali, Susanna, Rondelli, Francesca, Rinaldi, Rita, D’Angelo, Roberto, Nicodemo, Marianna, Mondini, Susanna, Sambati, Luisa, Asioli, Gian Maria, Rossi, Simone, Santoro, Rossella, Cretella, Lucia, Ferrari, Susy, Spinardi, Luca, Faccioli, Luca, Fanti, Stefano, Paccagnella, Andrea, Pierucci, Elisabetta, Casadei, Beatrice, Pellegrini, Cinzia, Zinzani, Pier Luigi, Bonafè, Massimiliano, Cortelli, Pietro, Bonifazi, Francesca, and Guarino, Maria

Published
2023
Full Text
View/download PDF

11. CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells

Author

Storci, Gianluca, primary, De Felice, Francesco, additional, Ricci, Francesca, additional, Santi, Spartaco, additional, Messelodi, Daria, additional, Bertuccio, Salvatore Nicola, additional, Laprovitera, Noemi, additional, Dicataldo, Michele, additional, Rossini, Lucrezia, additional, De Matteis, Serena, additional, Casadei, Beatrice, additional, Vaglio, Francesca, additional, Ursi, Margherita, additional, Barbato, Francesco, additional, Roberto, Marcello, additional, Guarino, Maria, additional, Asioli, Gian Maria, additional, Arpinati, Mario, additional, Cortelli, Pietro, additional, Maffini, Enrico, additional, Tomassini, Enrica, additional, Tassoni, Marta, additional, Cavallo, Carola, additional, Iannotta, Francesco, additional, Naddeo, Maria, additional, Tazzari, Pier Luigi, additional, Dan, Elisa, additional, Pellegrini, Cinzia, additional, Guadagnuolo, Serafina, additional, Carella, Matteo, additional, Sinigaglia, Barbara, additional, Pirazzini, Chiara, additional, Severi, Caterina, additional, Garagnani, Paolo, additional, Kwiatkowska, Katarzyna Malgorzata, additional, Ferracin, Manuela, additional, Zinzani, Pier Luigi, additional, Bonafè, Massimiliano, additional, and Bonifazi, Francesca, additional

Published
2024
Full Text
View/download PDF

12. Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity

Author

Pensato, Umberto, Amore, Giulia, D’Angelo, Roberto, Rinaldi, Rita, Nicodemo, Marianna, Rondelli, Francesca, Mondini, Susanna, Santoro, Rossella, Sammali, Susanna, Farolfi, Andrea, Spinardi, Luca, Faccioli, Luca, Casadei, Beatrice, Dicataldo, Michele, Bonifazi, Francesca, Zinzani, Pierluigi, Cortelli, Pietro, Stracciari, Andrea, and Guarino, Maria

Published
2022
Full Text
View/download PDF

14. Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study.

Author

Casadei, Beatrice, Conti, Gabriele, Barone, Monica, Turroni, Silvia, Guadagnuolo, Serafina, Broccoli, Alessandro, Brigidi, Patrizia, Argnani, Lisa, and Zinzani, Pier Luigi

Subjects
IMMUNE checkpoint inhibitors, END of treatment, GUT microbiome, SURVIVAL rate, LYMPHOMAS
Abstract

Biomarkers for immune checkpoint inhibitors (ICIs) response and resistance include PD‐L1 expression and other environmental factors, among which the gut microbiome (GM) is gaining increasing interest especially in lymphomas. To explore the potential role of GM in this clinical issue, feces of 30 relapsed/refractory lymphoma (Hodgkin and primary mediastinal B‐cell lymphoma) patients undergoing ICIs were collected from start to end of treatment (EoT). GM was profiled through Illumina, that is, 16S rRNA sequencing, and subsequently processed through a bioinformatics pipeline. The overall response rate to ICIs was 30.5%, with no association between patients clinical characteristics and response/survival outcomes. Regarding GM, responder patients showed a peculiar significant enrichment of Lachnospira, while non‐responder ones showed higher presence of Enterobacteriaceae (at baseline and maintained till EoT). Recognizing patient‐related factors that may influence response to ICIs is becoming critical to optimize the treatment pathway of heavily pretreated, young patients with a potentially long‐life expectancy. These preliminary results indicate potential early GM signatures of ICIs response in lymphoma, which could pave the way for future research to improve patients prognosis with new adjuvant strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

Author

Rossi, Alessandra, Orecchioni, Stefania, Falvo, Paolo, Tabanelli, Valentina, Baiardi, Elena, Agostinelli, Claudio, Melle, Federica, Motta, Giovanna, Calleri, Angelica, Fiori, Stefano, Corsini, Chiara, Casadei, Beatrice, Mazzara, Saveria, Vitolo, Umberto, Bertolini, Francesco, Zinzani, Pier Luigi, Alcalay, Myriam, Pelicci, Pier Giuseppe, Pileri, Stefano, Tarella, Corrado, and Derenzini, Enrico

Published
2022
Full Text
View/download PDF

17. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Author

Merryman, Reid W., Castagna, Luca, Giordano, Laura, Ho, Vincent T., Corradini, Paolo, Guidetti, Anna, Casadei, Beatrice, Bond, David A., Jaglowski, Samantha, Spinner, Michael A., Arai, Sally, Lowsky, Robert, Shah, Gunjan L., Perales, Miguel-Angel, De Colella, Jean Marc Schiano, Blaise, Didier, Herrera, Alex F., Shouse, Geoffrey, Spilleboudt, Chloe, Ansell, Stephen M., Nieto, Yago, Badar, Talha, Hamadani, Mehdi, Feldman, Tatyana A., Dahncke, Lori, Singh, Anurag K., McGuirk, Joseph P., Nishihori, Taiga, Chavez, Julio, Serritella, Anthony V., Kline, Justin, Mohty, Mohamad, Dulery, Remy, Stamatoulas, Aspasia, Houot, Roch, Manson, Guillaume, Moles-Moreau, Marie-Pierre, Orvain, Corentin, Bouabdallah, Kamal, Modi, Dipenkumar, Ramchandren, Radhakrishnan, Lekakis, Lazaros, Beitinjaneh, Amer, Frigault, Matthew J., Chen, Yi-Bin, Lynch, Ryan C., Smith, Stephen D., Rao, Uttam, Byrne, Michael, Romancik, Jason T., Cohen, Jonathon B., Nathan, Sunita, Phillips, Tycel, Joyce, Robin M., Rahimian, Maryam, Bashey, Asad, Ballard, Hatcher J., Svoboda, Jakub, Torri, Valter, Sollini, Martina, De Philippis, Chiara, Magagnoli, Massimo, Santoro, Armando, Armand, Philippe, Zinzani, Pier Luigi, and Carlo-Stella, Carmelo

Published
2021
Full Text
View/download PDF

19. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study

Author

Pagano, Livio, Criscuolo, Marianna, Broccoli, Alessandro, Piciocchi, Alfonso, Varettoni, Marzia, Galli, Eugenio, Anastasia, Antonella, Cantonetti, Maria, Trentin, Livio, Kovalchuk, Sofia, Orsucci, Lorella, Frustaci, Annamaria, Spolzino, Angelica, Volpetti, Stefano, Annibali, Ombretta, Storti, Sergio, Stelitano, Caterina, Marchesi, Francesco, Offidani, Massimo, Casadei, Beatrice, Nizzoli, Maria Elena, De Luca, Maria Lucia, Fianchi, Luana, Motta, Marina, Guarnera, Luca, Simonetti, Edoardo, Visentin, Andrea, Vassallo, Francesco, Deodato, Marina, Sarlo, Chiara, Olivieri, Attilio, Falini, Brunangelo, Pulsoni, Alessandro, Tiacci, Enrico, and Zinzani, Pier Luigi

Published
2022
Full Text
View/download PDF

20. The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation.

Author

Broccoli, Alessandro, Argnani, Lisa, Gugliotta, Gabriele, Pellegrini, Cinzia, Casadei, Beatrice, Bagnato, Gianmarco, Gentilini, Marianna, Stefoni, Vittorio, and Zinzani, Pier Luigi

Subjects
STEM cell transplantation, MEDICAL protocols, RESEARCH funding, RITUXIMAB, DESCRIPTIVE statistics, RETROSPECTIVE studies, MANN Whitney U Test, KAPLAN-Meier estimator, LOG-rank test, DATA analysis software, B cell lymphoma, ADULTS
Abstract

Introduction Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells transplantation (ASCT) is debated. Patients and Methods Between 2004 and 2020, 50 patients with BL were treated with the Berlin-Frankfurt-Münster (BFM). Treatment plan consisted of 3 blocks, A (ifosfamide, vincristine, methotrexate, etoposide, and cytarabine), B (vincristine, cyclophosphamide, methotrexate, and doxorubicin), and C (vindesine, methotrexate, etoposide, and cytarabine), each repeated twice, every 28 days. Rituximab was given at day 1 each block. Intrathecal prophylaxis was given once per each block. ASCT was scheduled at the end of the 6 blocks after conditioning. Results Median age at onset was 38 years (range 16-72); stages III-IV disease was observed in 82% of cases; bulky disease occurred in 44% of the patients, with B-symptoms in 38%. Stem cell harvest was performed in 72% of patients, who all received a subsequent ASCT. The full 6 blocks treatment was completed in 70% of the patients. The overall response rate was 74%, with a complete response rate of 60%. Ten-year overall survival and progression-free survival were 83.7% and 76.0%, respectively, without reaching the median. Ten-year disease-free survival was 80.3%. Grades 3-4 neutropenia, thrombocytopenia, anemia, and mucositis were seen in 96%, 60%, 32%, and 24% of patients. Infections occurred in 60% of patients. Conclusion Intensive treatment according to BFM protocol, with rituximab and ASCT, appears feasible, safe, and highly effective in adult patients with BL, as confirmed by long-term survival rates reflecting response maintenance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Author

Voltin, Conrad-Amadeus, primary, Paccagnella, Andrea, additional, Winkelmann, Michael, additional, Heger, Jan-Michel, additional, Casadei, Beatrice, additional, Beckmann, Laura, additional, Herrmann, Ken, additional, Dekorsy, Franziska J., additional, Kutsch, Nadine, additional, Borchmann, Peter, additional, Fanti, Stefano, additional, Kunz, Wolfgang G., additional, Subklewe, Marion, additional, Kobe, Carsten, additional, Zinzani, Pier Luigi, additional, Stelljes, Matthias, additional, Roth, Katrin S., additional, Drzezga, Alexander, additional, Noppeney, Richard, additional, Rahbar, Kambiz, additional, Reinhardt, H. Christian, additional, von Tresckow, Bastian, additional, Seifert, Robert, additional, Albring, Jörn C., additional, Blumenberg, Viktoria, additional, Farolfi, Andrea, additional, Flossdorf, Sarah, additional, Gödel, Philipp, additional, and Hanoun, Christine, additional

Published
2023
Full Text
View/download PDF

23. Intracranial pressure management in fulminant cerebral oedema after CAR T‐cell therapy: Not all is lost!

Author

Asioli, Gian Maria, primary, Castioni, Carlo Alberto, additional, Zinzani, Pier Luigi, additional, Casadio, Maria Chiara, additional, Pierucci, Elisabetta, additional, Casadei, Beatrice, additional, Spinardi, Luca, additional, Pellegrini, Cinzia, additional, Bonafé, Massimiliano, additional, Maffini, Enrico, additional, Guarino, Maria, additional, Cortelli, Pietro, additional, and Bonifazi, Francesca, additional

Published
2023
Full Text
View/download PDF

28. Intracranial pressure management in fulminant cerebral oedema after CAR T‐cell therapy: Not all is lost!

Author

Asioli, Gian Maria, Castioni, Carlo Alberto, Zinzani, Pier Luigi, Casadio, Maria Chiara, Pierucci, Elisabetta, Casadei, Beatrice, Spinardi, Luca, Pellegrini, Cinzia, Bonafé, Massimiliano, Maffini, Enrico, Guarino, Maria, Cortelli, Pietro, and Bonifazi, Francesca

Subjects
INTRACRANIAL pressure, CEREBRAL edema, BREAST, CHIMERIC antigen receptors, NEUROLOGICAL disorders, T cells
Abstract

This article discusses a case of fulminant cerebral edema (FCE) following CAR T-cell therapy, a treatment for certain types of cancer. FCE is a rare but severe complication that can lead to brain death within 24 hours. The patient in this case was successfully treated with prompt neurointensive support and immunosuppressive anti-cytokine therapy. The article emphasizes the importance of managing intracranial pressure (ICP) to prevent brain damage and highlights the need for aggressive neurointensive measures in addition to immunosuppressive therapy. The underlying pathophysiology of FCE is not fully understood, but the disruption of the blood-brain barrier and cytokine-mediated inflammation are believed to play a role. The article concludes that FCE is a potentially reversible complication and that early intervention is crucial for a positive outcome. [Extracted from the article]

Published
2024
Full Text
View/download PDF

29. S231: PRIMARY MEDIASTINAL B-CELL LYMPHOMA HAVE A SUPERIOR OUTCOME COMPARED TO DIFFUSE LARGE-B-CELL LYMPHOMA TREATED WITH AXICABTAGENE CILOLEUCEL IN THE CART-SIE REAL LIFE ITALIAN STUDY

Author

Chiappella, Annalisa, primary, Dodero, Anna, additional, Guidetti, Anna, additional, Ljevar, Silva, additional, Pennisi, Martina, additional, Casadei, Beatrice, additional, Galli, Eugenio, additional, Rocco, Alice DI, additional, Cutini, Ilaria, additional, Barbui, Anna Maria, additional, Bramanti, Stefania, additional, Musso, Maurizio, additional, Tisi, Maria Chiara, additional, Carrabba, Matteo Giovanni, additional, Martino, Massimo, additional, Farina, Mirko, additional, Botto, Barbara, additional, Grillo, Giovanni, additional, Ladetto, Marco, additional, Olivieri, Jacopo, additional, Arcaini, Luca, additional, Bermema, Anisa, additional, Miceli, Rosalba, additional, Chiusolo, Patrizia, additional, Zinzani, Pier Luigi, additional, and Corradini, Paolo, additional

Published
2023
Full Text
View/download PDF

30. P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE

Author

Rusconi, Chiara, primary, Ricci, Francesca, additional, Daffini, Rosa, additional, Casadei, Beatrice, additional, Ruggero Zilioli, Vittorio, additional, Mazzon, Federico, additional, Marasco, Vincenzo, additional, Calabretta, Eleonora, additional, Pagani, Chiara, additional, Argnani, Lisa, additional, Muzi, Cristina, additional, Guidetti, Anna, additional, Rodari, Marcello, additional, Passi, Angela, additional, Iadecola, Sara, additional, Cairoli, Roberto, additional, Luigi Zinzani, Pier, additional, Re, Alessandro, additional, Corradini, Paolo, additional, and Santoro, Armando, additional

Published
2023
Full Text
View/download PDF

31. S228: POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).

Author

Dodero, Anna, primary, Guidetti, Anna, additional, Chiappella, Annalisa, additional, Ljevar, Silva, additional, Pennisi, Martina, additional, Zinzani, Pier Luigi, additional, Casadei, Beatrice, additional, Bramanti, Stefania, additional, Santoro, Armando, additional, Chiusolo, Patrizia, additional, Rocco, Alice DI, additional, Palma, Martina DI, additional, Tisi, Maria Chiara, additional, Cutini, Ilaria, additional, Carrabba, Matteo, additional, Musso, Maurizio, additional, Martino, Massimo, additional, Barbui, Anna Maria, additional, Novo, Mattia, additional, Grillo, Giovanni, additional, Battista, Martalisa, additional, Zanni, Manuela, additional, Arcaini, Luca, additional, Miceli, Rosalba, additional, Magni, Martina, additional, Carniti, Cristiana, additional, and Corradini, Paolo, additional

Published
2023
Full Text
View/download PDF

32. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection

Author

Pasquini, Zeno, primary, Toschi, Alice, additional, Casadei, Beatrice, additional, Pellegrini, Cinzia, additional, D’Abramo, Alessandra, additional, Vita, Serena, additional, Beccacece, Alessia, additional, Bussini, Linda, additional, Chionsini, Maria Clara, additional, Dentale, Nicola, additional, Cantiani, Alessia, additional, Lazzarotto, Tiziana, additional, Bartoletti, Michele, additional, Nicastri, Emanuele, additional, Zinzani, Pierluigi, additional, Giannella, Maddalena, additional, and Viale, Pierluigi, additional

Published
2023
Full Text
View/download PDF

33. Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival

Author

Tumedei, Maria Maddalena, primary, Piccinini, Filippo, additional, Azzali, Irene, additional, Pirini, Francesca, additional, Bravaccini, Sara, additional, De Matteis, Serena, additional, Agostinelli, Claudio, additional, Castellani, Gastone, additional, Zanoni, Michele, additional, Cortesi, Michela, additional, Vergani, Barbara, additional, Leone, Biagio Eugenio, additional, Righi, Simona, additional, Gazzola, Anna, additional, Casadei, Beatrice, additional, Gentilini, Davide, additional, Calzari, Luciano, additional, Limarzi, Francesco, additional, Sabattini, Elena, additional, Pession, Andrea, additional, Tazzari, Marcella, additional, and Bertuzzi, Clara, additional

Published
2023
Full Text
View/download PDF

34. PET/CT in Non-Hodgkin Lymphoma: An Update

Author

Zanoni, Lucia, primary, Bezzi, Davide, additional, Nanni, Cristina, additional, Paccagnella, Andrea, additional, Farina, Arianna, additional, Broccoli, Alessandro, additional, Casadei, Beatrice, additional, Zinzani, Pier Luigi, additional, and Fanti, Stefano, additional

Published
2023
Full Text
View/download PDF

35. Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report.

Author

Zoli, Sabrina, Pellegrini, Cinzia, Casadei, Beatrice, Broccoli, Alessandro, Argnani, Lisa, Nanni, Laura, Stefoni, Vittorio, and Zinzani, Pier Luigi

Subjects
DIFFUSE large B-cell lymphomas, LENALIDOMIDE
Abstract

Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), there are no uniform recommendations for second-line treatment in case of relapse. Case Presentation: Here, we present the case of an elderly relapsed/refractory PCDLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide. Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma.

Author

Lolli, Ginevra, Argnani, Lisa, Gini, Guido, Casadei, Beatrice, Pellegrini, Cinzia, Tani, Monica, Pavone, Vincenzo, Cimminiello, Michele, Bonifazi, Francesca, and Zinzani, Pier Luigi

Subjects
DIFFUSE large B-cell lymphomas, HISTOCOMPATIBILITY antigens, CHIMERIC antigen receptors, T cells, STEM cell transplantation
Abstract

This article discusses the use of pixantrone as a bridging therapy (BT) for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are undergoing chimeric antigen receptor (CAR) T-cell therapy or allogeneic stem cell transplantation (allo-SCT). Pixantrone is a drug with low cardiotoxic potential and few side effects. The study, conducted in Italy, collected data from 13 patients who received pixantrone as BT. The results showed that pixantrone effectively controlled lymphoma-related symptoms and allowed patients to proceed with subsequent planned therapy. The overall response rate (ORR) was 23% after pixantrone, and the ORR after CAR T-cell therapy or allo-SCT was 76.9%. Adverse events were limited, and no cardiotoxicities were reported. The median overall survival was 10.5 months, and the median progression-free survival was 5.2 months. The authors recommend considering pixantrone as a valid and widely available option for bridging therapy in DLBCL patients. [Extracted from the article]

Published
2023
Full Text
View/download PDF

37. Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

Author

Liu, Chun, primary, Cojutti, Pier Giorgio, additional, Giannella, Maddalena, additional, Roberto, Marcello, additional, Casadei, Beatrice, additional, Cristiano, Gianluca, additional, Papayannidis, Cristina, additional, Vianelli, Nicola, additional, Zinzani, Pier Luigi, additional, Viale, Pierluigi, additional, Bonifazi, Francesca, additional, and Pea, Federico, additional

Published
2023
Full Text
View/download PDF

39. Frequent ZNF217mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma

Author

Briest, Franziska, Noerenberg, Daniel, Hennch, Cornelius, Yoshida, Kenichi, Hablesreiter, Raphael, Nimo, Jose, Sasca, Daniel, Kirchner, Marieluise, Mansouri, Larry, Inoue, Yoshikage, Wiegand, Laura, Staiger, Annette M., Casadei, Beatrice, Korkolopoulou, Penelope, Weiner, January, Lopez-Guillermo, Armando, Warth, Arne, Schneider, Tamás, Nagy, Ákos, Klapper, Wolfram, Hummel, Michael, Kanellis, George, Anagnostopoulos, Ioannis, Mertins, Philipp, Bullinger, Lars, Rosenquist, Richard, Vassilakopoulos, Theodoros P., Ott, German, Ogawa, Seishi, and Damm, Frederik

Abstract

Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217alterations remain unknown, we comprehensively evaluated their impact in PMBCL. Targeted sequencing identified genetic lesions affecting ZNF217in 33% of 157 PMBCL patients. Subsequent gene expression profiling (n= 120) revealed changes in cytokine and interferon signal transduction in ZNF217-aberrant PMBCL cases. In vitro, knockout of ZNF217led to changes in chromatin accessibility interfering with binding motifs for crucial lymphoma-associated transcription factors. This led to disturbed expression of interferon-responsive and inflammation-associated genes, altered cell behavior, and aberrant differentiation. Mass spectrometry demonstrates that ZNF217 acts within a histone modifier complex containing LSD1, CoREST and HDAC and interferes with H3K4 methylation and H3K27 acetylation. Concluding, our data suggest non-catalytic activity of ZNF217, which directs histone modifier complex function and controls B cell differentiation-associated patterns of chromatin structure.

Published
2023
Full Text
View/download PDF

41. Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity

Author

De Matteis, Serena, primary, Dicataldo, Michele, additional, Casadei, Beatrice, additional, Storci, Gianluca, additional, Laprovitera, Noemi, additional, Arpinati, Mario, additional, Maffini, Enrico, additional, Cortelli, Pietro, additional, Guarino, Maria, additional, Vaglio, Francesca, additional, Naddeo, Maria, additional, Sinigaglia, Barbara, additional, Zazzeroni, Luca, additional, Guadagnuolo, Serafina, additional, Tomassini, Enrica, additional, Bertuccio, Salvatore Nicola, additional, Messelodi, Daria, additional, Ferracin, Manuela, additional, Bonafè, Massimiliano, additional, Zinzani, Pier Luigi, additional, and Bonifazi, Francesca, additional

Published
2023
Full Text
View/download PDF

43. Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Author

Boussi, Leora S, primary, Koh, Min Jung, additional, Han, Xinyi, additional, Peng, Luke, additional, Koh, Min Ji, additional, Eche, Ijeoma, additional, Ford, Josie Germain, additional, Singh, Shambhavi, additional, Miranda, Eliana, additional, Chiattone, Carlos S., additional, Van Der Weyden, Carrie, additional, Prince, Henry Miles, additional, Foss, Francine M., additional, Yoon, Sang Eun, additional, Kim, Won-Seog, additional, Panchoo, Girisha, additional, Verburgh, Estelle, additional, Cuenca Alturas, Jackielyn, additional, Al-mansour, Mubarak, additional, Manni, Martina, additional, Federico, Massimo, additional, Cabrera, Maria Elena, additional, Casadei, Beatrice, additional, Zinzani, Pier Luigi, additional, Yoshida, Noriaki, additional, Okatani, Takeshi, additional, Merrill, Mwanasha H., additional, Jacobsen, Eric D, additional, O'Connor, Owen A., additional, Marchi, Enrica, additional, and Jain, Salvia, additional

Published
2022
Full Text
View/download PDF

44. Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Author

Broccoli, Alessandro, primary, Argnani, Lisa, additional, Nanni, Laura, additional, Bagnato, Gianmarco, additional, Carella, Matteo, additional, Casadei, Beatrice, additional, Coppola, Paolo Elia, additional, Gugliotta, Gabriele, additional, Lolli, Ginevra, additional, Gentilini, Marianna, additional, Morigi, Alice, additional, Pellegrini, Cinzia, additional, Stefoni, Vittorio, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

45. Critical Role of Hodgkin Lymphoma Cells-Derived Large and Small Extracellular Vesicles in the Regulation of the Immune-Inflammatory Microenvironment

Author

Maltoni, Filippo, primary, Ciardiello, Chiara, additional, Nanni, Laura, additional, Barone, Martina, additional, Narimanfar, Ghazal, additional, Casadei, Beatrice, additional, Argnani, Lisa, additional, Broccoli, Alessandro, additional, Forte, Dorian, additional, Budillon, Alfredo, additional, Zinzani, Pier Luigi, additional, and Catani, Lucia, additional

Published
2022
Full Text
View/download PDF

46. Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy

Author

De Matteis, Serena, primary, Casadei, Beatrice, additional, Lolli, Ginevra, additional, Dicataldo, Michele, additional, Barbato, Francesco, additional, Dan, Elisa, additional, Paccagnella, Andrea, additional, Sinigaglia, Barbara, additional, Bertuzzi, Clara, additional, Arcari, Annalisa, additional, Zazzeroni, Luca, additional, Bernuzzi, Patrizia, additional, Laprovitera, Noemi, additional, Storci, Gianluca, additional, Bertuccio, Salvatore Nicola, additional, Ferracin, Manuela, additional, Bonafè, Massimiliano, additional, Zinzani, Pier Luigi, additional, and Bonifazi, Francesca, additional

Published
2022
Full Text
View/download PDF

47. NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma

Author

Vegliante, Maria Carmela, primary, Mazzara, Saveria, additional, Zaccaria, Gian Maria, additional, De Summa, Simona, additional, Esposito, Flavia, additional, Melle, Federica, additional, Motta, Giovanna, additional, Sapienza, Maria Rosaria, additional, Opinto, Giuseppina, additional, Volpe, Giacomo, additional, Bucci, Antonella, additional, Gargano, Grazia, additional, Enjuanes, Anna, additional, Tabanelli, Valentina, additional, Fiori, Stefano, additional, Minoia, Carla, additional, Clemente, Felice, additional, Negri, Antonio, additional, Gulino, Alessandro, additional, Morello, Gaia, additional, Scattone, Anna, additional, Zito, Alfredo F., additional, Tommasi, Stefania, additional, Agostinelli, Claudio, additional, Vitolo, Umberto, additional, Chiappella, Annalisa, additional, Barbui, Anna Maria, additional, Derenzini, Enrico, additional, Zinzani, Pier Luigi, additional, Casadei, Beatrice, additional, Rivas‐Delgado, Alfredo, additional, López‐Guillermo, Armando, additional, Campo, Elias, additional, Moschetta, Antonio, additional, Guarini, Attilio, additional, Pileri, Stefano A., additional, and Ciavarella, Sabino, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results